Explore

Rapid Read Rapid Read
MIT-Led Study Develops Adjuvant to Enhance Mucosal Immunity in Polio Vaccines

MIT-Led Study Develops Adjuvant to Enhance Mucosal Immunity in Polio Vaccines

Researchers at the Massachusetts Institute of Technology have developed an experimental adjuvant that could enhance mucosal immunity when used with injectable polio vaccines. The adjuvant, Am80, is delivered using lipid nanoparticles, allowing for a slow release that stimulates immune cells to target the mucosal lining of the intestine. This approach aims to provide the benefits of the oral polio vaccine, which induces mucosal immunity, without its associated risks. Initial tests in rats have shown promising results, with increased production of antibodies necessary for mucosal immunity.
Rapid Read Rapid Read
MIT Researchers Develop Adjuvant to Enhance Injectable Polio Vaccine's Mucosal Immunity

MIT Researchers Develop Adjuvant to Enhance Injectable Polio Vaccine's Mucosal Immunity

Researchers at the Massachusetts Institute of Technology have developed a new adjuvant that could enhance the mucosal immunity of the injectable polio vaccine. The injectable form of the polio vaccine is effective at preventing illness but does not block virus transmission as effectively as the oral version. The oral vaccine induces a mucosal immune response in the gastrointestinal tract, which is the primary site of virus exposure. However, due to a small risk of infection, several countries have stopped using the oral vaccine. The new adjuvant, known as Am80, is delivered with a lipid nanoparticle that releases it slowly, allowing for a sustained immune response. This approach aims to combine the safety of the injectable vaccine with the mucosal immunity benefits of the oral vaccine, potentially aiding in polio eradication efforts.
Rapid Read Rapid Read
MIT Study Explores Enhanced Mucosal Immunity for Injectable Polio Vaccines

MIT Study Explores Enhanced Mucosal Immunity for Injectable Polio Vaccines

Researchers at the Massachusetts Institute of Technology (MIT) have developed an experimental adjuvant that could enhance mucosal immunity when used with injectable polio vaccines. The study, published in Science Advances, suggests that the adjuvant, known as Am80, can be delivered using lipid nanoparticles to stimulate immune cells to target the mucosal lining of the intestine. This approach aims to combine the safety of the injectable polio vaccine with the mucosal immunity typically provided by the oral polio vaccine, which some countries have stopped using due to a small risk of infection.
Rapid Read Rapid Read
Chitosan Nanoparticles Show Promise for Stable, Needle-Free Vaccines

Chitosan Nanoparticles Show Promise for Stable, Needle-Free Vaccines

A recent review highlights the potential of chitosan-based nanoparticles to revolutionize vaccine delivery by making them more stable, mucosal, and needle-free. Chitosan, a natural polymer, can protect fragile antigens and enhance immune responses, offering a solution to the limitations of conventional vaccines that rely on cold-chain storage and are less effective at mucosal surfaces. The review, published in npj Vaccines, discusses how chitosan nanoparticles can be engineered to improve solubility, stability, and antigen delivery. These nanoparticles could enable needle-free vaccination strategies, reducing logistical challenges and improving accessibility.
Rapid Read Rapid Read
Efforts to Develop Vaccine for Ebola Bundibugyo Strain Intensify

Efforts to Develop Vaccine for Ebola Bundibugyo Strain Intensify

Global vaccine non-profits are accelerating efforts to develop a vaccine for the Bundibugyo strain of Ebola, which is driving the current outbreak in the Democratic Republic of Congo and Uganda. The Coalition for Epidemic Preparedness Innovation (CEPI) and Gavi have committed over $100 million to fast-track research and development of vaccine candidates. CEPI is investing $62 million in three vaccine candidates, while Gavi is contributing $40 million to create a market for a successful vaccine. The urgency stems from the strain's rapid spread and the lack of approved vaccines or treatments for Bundibugyo.
TheStreet TheStreet
Moderna gets good news as it searches for life after Covid

Moderna gets good news as it searches for life after Covid

Moderna (MRNA) was one of the big beneficiaries of the Covid pandemic, producing tens of billions of dollars in vaccine sales and becoming one of the most carefully watched businesses in biotechnology. Since then, the task has been to prove that the accomplishment was not a fluke. As Covid-related ...
Rapid Read Rapid Read
POP Biotechnologies Receives $9.7 Million CEPI Funding for Vaccine Development

POP Biotechnologies Receives $9.7 Million CEPI Funding for Vaccine Development

POP Biotechnologies, a Buffalo-based biotech company, has secured up to $9.7 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its SNAP nanoparticle vaccine platform into Phase 1 clinical trials. The funding will support the development of a vaccine candidate targeting H5N1 avian influenza, leveraging the SNAP platform's ability to enhance immune responses through protein-tagging technology. This investment builds on a previous $1.5 million award from CEPI, aimed at accelerating the development of vaccines against epidemic and pandemic threats.
Rapid Read Rapid Read
Cross-Reactive T Cells Offer Hope for Broad Vaccines Against Measles and Nipah Virus

Cross-Reactive T Cells Offer Hope for Broad Vaccines Against Measles and Nipah Virus

Researchers at the La Jolla Institute for Immunology have discovered that cross-reactive T cells could be key in developing broad vaccines or treatments for paramyxoviruses, including measles and Nipah virus. The study, led by Alessandro Sette, PhD, mapped human CD4+ T cell epitopes across these viruses, revealing conserved regions that could trigger immune responses against multiple paramyxovirus species. This finding suggests that instead of targeting individual viruses, vaccines could be designed to activate these cross-reactive T cells, offering protection against a wider range of viruses within the family. The research highlights the potential for new vaccine strategies that leverage existing population immunity.
Trendline Trendline
Advancements in mRNA Therapeutics Highlight Potential for Disease Treatment

Advancements in mRNA Therapeutics Highlight Potential for Disease Treatment

Advancements in mRNA Therapeutics Highlight Potential for Disease Treatment
Trendline Trendline
Co-Diagnostics Advances Ebola PCR Test Development with CoSara Joint Venture

Co-Diagnostics Advances Ebola PCR Test Development with CoSara Joint Venture

Co-Diagnostics Advances Ebola PCR Test Development with CoSara Joint Venture
Rapid Read Rapid Read
Understanding Ebola: Challenges in Treatment and Prevention Amidst New Outbreaks

Understanding Ebola: Challenges in Treatment and Prevention Amidst New Outbreaks

Ebola, a highly lethal virus, continues to pose significant challenges in treatment and prevention, particularly in resource-limited settings. The virus attacks key immune cells, delaying the body's adaptive immune response and allowing rapid spread throughout the body. This often leads to severe symptoms and high mortality rates. Basic supportive care, such as fluid replacement and blood pressure management, can improve survival rates, but such care is often difficult to deliver in outbreak regions due to limited resources. The current outbreak in the Democratic Republic of Congo highlights these challenges, as ongoing conflict and under-resourced medical facilities hinder effective response efforts.
AP News AP News
Tools to fight hantavirus show promise despite limited funding. Now researchers hope to continue

Tools to fight hantavirus show promise despite limited funding. Now researchers hope to continue

There were no treatments or vaccines to protect people during the recent hantavirus outbreak on a cruise ship